The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Duchenne Muscular Dystrophy Therapeutics Market Research Report 2025
Synopsis
Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.
The global Duchenne Muscular Dystrophy Therapeutics market was valued at US$ 1329.2 million in 2023 and is anticipated to reach US$ 5209.6 million by 2030, witnessing a CAGR of 21.1% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Duchenne Muscular Dystrophy Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Duchenne Muscular Dystrophy Therapeutics.
Report Scope
The Duchenne Muscular Dystrophy Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Duchenne Muscular Dystrophy Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Duchenne Muscular Dystrophy Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bristol-Myers Squibb
FibroGen (US)
Italfarmaco (Italy)
Marathon
NS Pharma (US)
PTC Therapeutics (US)
Pfizer
ReveraGen BioPharma (US)
Santhera Pharmaceuticals (Switzerland)
Sarepta Therapeutics (US)
Segment by Type
Pain Management Drugs
Corticosteroids
Prednisolone
Prednisone
Deflazacort
Segment by Application
Hospitals
Clinics
Home Care
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Duchenne Muscular Dystrophy Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.
The global Duchenne Muscular Dystrophy Therapeutics market was valued at US$ 1329.2 million in 2023 and is anticipated to reach US$ 5209.6 million by 2030, witnessing a CAGR of 21.1% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Duchenne Muscular Dystrophy Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Duchenne Muscular Dystrophy Therapeutics.
Report Scope
The Duchenne Muscular Dystrophy Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Duchenne Muscular Dystrophy Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Duchenne Muscular Dystrophy Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bristol-Myers Squibb
FibroGen (US)
Italfarmaco (Italy)
Marathon
NS Pharma (US)
PTC Therapeutics (US)
Pfizer
ReveraGen BioPharma (US)
Santhera Pharmaceuticals (Switzerland)
Sarepta Therapeutics (US)
Segment by Type
Pain Management Drugs
Corticosteroids
Prednisolone
Prednisone
Deflazacort
Segment by Application
Hospitals
Clinics
Home Care
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Duchenne Muscular Dystrophy Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Duchenne Muscular Dystrophy Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Pain Management Drugs
1.2.3 Corticosteroids
1.2.4 Prednisolone
1.2.5 Prednisone
1.2.6 Deflazacort
1.3 Market by Application
1.3.1 Global Duchenne Muscular Dystrophy Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Home Care
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Duchenne Muscular Dystrophy Therapeutics Market Perspective (2019-2030)
2.2 Duchenne Muscular Dystrophy Therapeutics Growth Trends by Region
2.2.1 Global Duchenne Muscular Dystrophy Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Duchenne Muscular Dystrophy Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Duchenne Muscular Dystrophy Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Duchenne Muscular Dystrophy Therapeutics Market Dynamics
2.3.1 Duchenne Muscular Dystrophy Therapeutics Industry Trends
2.3.2 Duchenne Muscular Dystrophy Therapeutics Market Drivers
2.3.3 Duchenne Muscular Dystrophy Therapeutics Market Challenges
2.3.4 Duchenne Muscular Dystrophy Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Duchenne Muscular Dystrophy Therapeutics Players by Revenue
3.1.1 Global Top Duchenne Muscular Dystrophy Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Duchenne Muscular Dystrophy Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Duchenne Muscular Dystrophy Therapeutics Revenue
3.4 Global Duchenne Muscular Dystrophy Therapeutics Market Concentration Ratio
3.4.1 Global Duchenne Muscular Dystrophy Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Duchenne Muscular Dystrophy Therapeutics Revenue in 2023
3.5 Duchenne Muscular Dystrophy Therapeutics Key Players Head office and Area Served
3.6 Key Players Duchenne Muscular Dystrophy Therapeutics Product Solution and Service
3.7 Date of Enter into Duchenne Muscular Dystrophy Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Duchenne Muscular Dystrophy Therapeutics Breakdown Data by Type
4.1 Global Duchenne Muscular Dystrophy Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Duchenne Muscular Dystrophy Therapeutics Forecasted Market Size by Type (2025-2030)
5 Duchenne Muscular Dystrophy Therapeutics Breakdown Data by Application
5.1 Global Duchenne Muscular Dystrophy Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Duchenne Muscular Dystrophy Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Duchenne Muscular Dystrophy Therapeutics Market Size (2019-2030)
6.2 North America Duchenne Muscular Dystrophy Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2019-2024)
6.4 North America Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Duchenne Muscular Dystrophy Therapeutics Market Size (2019-2030)
7.2 Europe Duchenne Muscular Dystrophy Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2019-2024)
7.4 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size (2019-2030)
9.2 Latin America Duchenne Muscular Dystrophy Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Detail
11.1.2 Bristol-Myers Squibb Business Overview
11.1.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Introduction
11.1.4 Bristol-Myers Squibb Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2019-2024)
11.1.5 Bristol-Myers Squibb Recent Development
11.2 FibroGen (US)
11.2.1 FibroGen (US) Company Detail
11.2.2 FibroGen (US) Business Overview
11.2.3 FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Introduction
11.2.4 FibroGen (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2019-2024)
11.2.5 FibroGen (US) Recent Development
11.3 Italfarmaco (Italy)
11.3.1 Italfarmaco (Italy) Company Detail
11.3.2 Italfarmaco (Italy) Business Overview
11.3.3 Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Introduction
11.3.4 Italfarmaco (Italy) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2019-2024)
11.3.5 Italfarmaco (Italy) Recent Development
11.4 Marathon
11.4.1 Marathon Company Detail
11.4.2 Marathon Business Overview
11.4.3 Marathon Duchenne Muscular Dystrophy Therapeutics Introduction
11.4.4 Marathon Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2019-2024)
11.4.5 Marathon Recent Development
11.5 NS Pharma (US)
11.5.1 NS Pharma (US) Company Detail
11.5.2 NS Pharma (US) Business Overview
11.5.3 NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Introduction
11.5.4 NS Pharma (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2019-2024)
11.5.5 NS Pharma (US) Recent Development
11.6 PTC Therapeutics (US)
11.6.1 PTC Therapeutics (US) Company Detail
11.6.2 PTC Therapeutics (US) Business Overview
11.6.3 PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Introduction
11.6.4 PTC Therapeutics (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2019-2024)
11.6.5 PTC Therapeutics (US) Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Detail
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Duchenne Muscular Dystrophy Therapeutics Introduction
11.7.4 Pfizer Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2019-2024)
11.7.5 Pfizer Recent Development
11.8 ReveraGen BioPharma (US)
11.8.1 ReveraGen BioPharma (US) Company Detail
11.8.2 ReveraGen BioPharma (US) Business Overview
11.8.3 ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Introduction
11.8.4 ReveraGen BioPharma (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2019-2024)
11.8.5 ReveraGen BioPharma (US) Recent Development
11.9 Santhera Pharmaceuticals (Switzerland)
11.9.1 Santhera Pharmaceuticals (Switzerland) Company Detail
11.9.2 Santhera Pharmaceuticals (Switzerland) Business Overview
11.9.3 Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Introduction
11.9.4 Santhera Pharmaceuticals (Switzerland) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2019-2024)
11.9.5 Santhera Pharmaceuticals (Switzerland) Recent Development
11.10 Sarepta Therapeutics (US)
11.10.1 Sarepta Therapeutics (US) Company Detail
11.10.2 Sarepta Therapeutics (US) Business Overview
11.10.3 Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Introduction
11.10.4 Sarepta Therapeutics (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2019-2024)
11.10.5 Sarepta Therapeutics (US) Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
